Luxvitae Therapeutics Inc.

SAN DIEGO, CA · CIK 0002052787 · Biotech · Private

AI-powered therapeutic discovery and drug development platform

luxvitae.tech →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$8.5M
1 Form D · Jan 2025
20 months since last filing
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$8,500,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1554BORAGEN INC——
1555CELLINFINITY BIO, INC.——
1556Raven Biomaterials LLC——
1557Luxvitae Therapeutics Inc.—$8.5M
1558Orbis Medicines——
1559TRANSPORIN, INC.——
1560Karuna Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Feng TianDirector · Executive Officer
  • Zhengyuan WangDirector
  • Xianzhong WuDirector

Patents

USPTO · 0 granted of 7
  • Duocarmycin Analogs And Applications Thereofapplication
  • Amino Acid Derivatives And Method Of Making The Sameapplication
  • Macrocyclic Ketone Compounds And Applications Thereofapplication
  • Duocarmycin Analogs And Applications Thereofapplication
  • Amino Acid Derivatives And Method Of Making The Sameapplication
  • Macrocyclic Ketone Compounds And Applications Thereofapplication
  • Macrocyclic Ketone Compounds And Applications Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.